Bibliography
- Muller AJ , ScherlePA: Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.Nat. Rev. Cancer6(8) , 613–625 (2006).
- Ball HJ , Sanchez-PerezA, WeiserSet al.: Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice.Gene396(1) , 203–213 (2007).
- Metz R , DuhadawayJB, KamasaniU, Laury-KleintopL, MullerAJ, PrendergastGC: Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.Cancer Res.67(15) , 7082–7087 (2007).
- Shimizu T , NomiyamaS, HirataF, HayaishiO: Indoleamine 2,3-dioxygenase. Purification and some properties.J. Biol. Chem.253(13) , 4700–4706 (1978).
- Yoshida R , HayaishiO: Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide.Proc. Natl Acad. Sci. USA75(8) , 3998–4000 (1978).
- Cady SG , SonoM: 1-methyl-DL-tryptophan, β-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan) , and β-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase.Arch. Biochem. Biophys.291 , 326–333 (1991).
- Mellor AL , SivakumarJ, ChandlerPet al.: Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.Nat. Immunol.2(1) , 64–68 (2001).
- Munn DH , ZhouM, AttwoodJTet al.: Prevention of allogeneic fetal rejection by tryptophan catabolism.Science281 , 1191–1193 (1998).
- Munn DH , ShafizadehE, AttwoodJT, BondarevI, PashineA, MellorAL: Inhibition of T cell proliferation by macrophage tryptophan catabolism.J. Exp. Med.189 , 1363–1372 (1999).
- Muller AJ , SharmaMD, ChandlerPRet al.: Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.Proc. Natl Acad. Sci. USA105(44) , 17073–17078 (2008).
- Dunn GP , OldLJ, SchreiberRD: The immunobiology of cancer immunosurveillance and immunoediting.Immunity21(2) , 137–148 (2004).
- Pertovaara M , HasanT, RaitalaAet al.: Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season.Clin. Exp. Immunol.150(2) , 274–278 (2007).
- Schroecksnadel K , WinklerC, DuftnerC, WirleitnerB, SchirmerM, FuchsD: Tryptophan degradation increases with stage in patients with rheumatoid arthritis.Clin. Rheumatol.25(3) , 334–337 (2006).
- Mandik-Nayak L , AllenPM: Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis.Immunol. Res.32(1–3) , 5–13 (2005).
- Scott GN , DuHadawayJ, PigottEet al.: The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity.J. Immunol.182(12) , 7509–7517 (2009).
- Muller AJ , DuhadawayJB, DonoverPS, Sutanto-WardE, PrendergastGC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.Nat. Med.11(3) , 312–319 (2005).
- Han Y , EnglertJA, YangR, DeludeRL, FinkMP: Ethyl pyruvate inhibits nuclear factor-κB-dependent signaling by directly targeting p65.J. Pharmacol. Exp. Ther.312(3) , 1097–1105 (2005).
- Sappington PL , CruzRJ Jr, Harada T et al.: The ethyl pyruvate analogues, diethyl oxaloproprionate, 2-acetamidoacrylate, and methyl-2-acetamidoacrylate, exhibit anti-inflammatory properties in vivo and/or in vitro. Biochem. Pharmacol.70(11) , 1579–1592 (2005).
- Uchiyama T , DeludeRL, FinkMP: Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion.Intensive Care Med.29(11) , 2050–2058 (2003).
- Yang R , GalloDJ, BaustJJet al.: Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock.Am. J. Physiol. Gastrointest. Liver Physiol.283(1) , G212–221 (2002).
- Yang R , HanX, DeludeRL, FinkMP: Ethyl pyruvate ameliorates acute alcohol-induced liver injury and inflammation in mice.J. Lab. Clin. Med.142(5) , 322–331 (2003).
- Yang R , UchiyamaT, AlberSMet al.: Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis.Crit. Care Med.32(7) , 1453–1459 (2004).
- Muller AJ , DuHadawayJB, JallerD, CurtisP, MetzR, PrendergastGC: Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.Cancer Res.70(5) , 1845–1853 (2010).
- Banerjee T , DuHadawayJB, GaspariPet al.: A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.Oncogene27(20) , 2851–2857 (2008).
- Gaspari P , BanerjeeT, MalachowskiWPet al.: Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.J. Med. Chem.49(2) , 684–692 (2006).
- Kumar S , MalachowskiWP, DuhadawayJBet al.: Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.J. Med. Chem.51(6) , 1706–1718 (2008).
- Baud V , KarinM: Is NF-κB a good target for cancer therapy? Hopes and pitfalls.Nat. Rev. Drug Discov.8(1) , 33–40 (2009).
- Weinstein IB : Cancer. Addiction to oncogenes – the Achilles heal of cancer.Science297(5578) , 63–64 (2002).
- Baban B , ChandlerP, McCoolD, MarshallB, MunnDH, MellorAL: Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific.J. Reprod. Immunol.61(2) , 67–77 (2004).